A Practical Diligence Framework for Early Medtech and Life-Science Deals

When you’re evaluating an early-stage medtech or life-science company, the science is often presented as settled and the risk located somewhere else. Good technical diligence inverts that: it asks where the evidence is actually thin, and what would have to be true for the claims to hold. Here’s a framework I use.

1. Trace the claim to its evidence. Start from the boldest claim in the deck and walk backward to the data behind it. Is there a direct line, or a series of inferential hops? The gap between what they showed and what they’re claiming is where most risk lives.

2. Interrogate the reference standard. How was ground truth established? If it rests on expert judgment — how many experts, what qualifications, what agreement, and how were disagreements resolved? A claim is only as strong as the standard it’s measured against.

3. Check independence and reproducibility. Has the result been reproduced — different operator, site, cohort? Or does it exist once, in the founders’ hands? Single-source results are hypotheses in costume.

4. Map the regulatory path honestly. What’s the actual route — 510(k), De Novo, PMA — and does the predicate/comparison logic hold? Teams frequently understate the evidence the path will demand. The plan should match the claim’s ambition.

5. Separate science risk from execution risk. Sometimes the science is sound and the team can’t execute; sometimes the reverse. Naming which one you’re underwriting changes the deal.

6. Pressure-test with someone who can build it. The sharpest diligence comes from someone who understands both the science and the engineering — who can tell whether the technical plan is feasible, not merely plausible.

The output of good diligence isn’t a thumbs up or down. It’s a clear map of what’s strong, what’s exposed, and which specific questions to ask next — so you enter the decision with your eyes open.

That’s exactly what a scientific and regulatory diligence memo delivers.